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Evaluation of Mucosal 5-HT Signaling and Potential Sex Differences in Motor Activity in the 
Experimental Autoimmune Encephalomyelitis Mouse Model of Multiple Sclerosis 
University of Vermont 




Multiple Sclerosis (MS) is an autoimmune disease that causes a myriad of symptoms, 
including cognitive, sensory, and motor deficits, as well as gastrointestinal (GI) dysmotility. We 
have previously demonstrated that male mice with experimental autoimmune encephalomyelitis 
(EAE), the predominant model for MS, have disrupted GI motility, but the mechanisms for this 
dysmotility are not understood, and potential sex differences have not been evaluated. Since 5-
hydroxytryptamine (5-HT; serotonin) is a mediator of motor and secretory reflexes in the gut, we 
investigated key elements of mucosal 5-HT signaling in the EAE mouse model of MS. Enzyme 
linked immunosorbent assay (ELISA) was used to evaluate 5-HT tissue levels as normalized by a 
bicinchoninic acid assay and RT-qPCR was used to evaluate mRNA expression for the rate 
limiting molecule in 5-HT synthesis, tryptophan hydroxylase 1 (Tph1), and the serotonin reuptake 
transporter (SERT), both of which were normalized to the housekeeping gene beta 2 microglobulin 
(B2M). Motility and fecal composition were also compared in female versus male mice with EAE. 
The mRNA expression for Tph1 was decreased in EAE mice, but levels of 5-HT in the tissue and 
SERT mRNA expression were unchanged. Furthermore, no differences were detected in colonic 
motility, fecal water content, or whole GI transit in female versus male mice with EAE. However, 
it was noted that male mice with EAE displayed peak GI dysfunction at day 21, whereas female 
mice with EAE showed peak GI dysfunction at day 27. These findings indicate that female and 
male mice present with similar levels of GI dysfunction over time, representing comparable 
models for motility disruption in EAE, and suggest that mechanisms other than altered 5-HT 




Multiple Sclerosis and GI Dysfunction 
Multiple Sclerosis (MS) is typically characterized as an inflammatory autoimmune disease 
of the central nervous system (CNS) in which T cells attack the myelin sheaths of axons resulting 
in scar tissue, sclerosis, and nerve fiber damage. This damage and loss of myelin creates a 
disruption of nerve signals resulting in a wide expanse of symptoms including movement 
disabilities (National Multiple Sclerosis Society, 2018). An overlooked component of these 
movement disabilities includes gastrointestinal (GI) motility, as up to two thirds of all MS patients 
report having bowel dysfunction, with constipation and fecal incontinence being the predominant 
symptoms (Future, Joy, & Richard B. Johnston, 2001; Levinthal et al., 2013; Preziosi et al., 2013). 
A recent report stated that approximately fifty percent of individuals with MS will experience 
constipation, with thirty percent of the MS population also experiencing fecal incontinence (Future 
et al., 2001). Despite the common prevalence of these symptoms and general GI dysfunction in 
the MS population, the exact etiology behind this dysfunction is still unclear. 
 A prominent experimental approach in attempting to understand these mechanisms is 
derived from the use of the experimental autoimmune encephalomyelitis (EAE) mouse model of 
MS. To this extent, a recent study by the Mawe laboratory (Spear et al., 2018) showed that male 
mice with EAE demonstrate altered GI function consistent with MS-related constipation, 
validating the model as a potential means of examining the molecular changes that might occur 
leading to the noted alterations in GI function. Furthermore, recent studies have indicated the 
involvement of the enteric nervous system (ENS) as a target of circulating auto-antibodies in MS 
and EAE (Spear et al., 2018; Wunsch et al., 2017). The ENS is the neuronal governing system of 
GI tract motor and secretory functions, and consists of cellular aspects and proteins that are similar 
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to those of the CNS. In this regard, the studies by the Mawe and Kürten labs (Spear et al., 2018; 
Wunsch et al., 2017) indicated that there is an involvement of autoantibodies in MS, which targets 
the neurons and glial cells of the ENS, similar to those that target the CNS, and might mediate 
components associated with GI dysfunction. However, despite these breakthrough findings, the 
exact neuronal mechanisms that lead to the alterations in motility are still unknown. 
 
The Role of Serotonin in GI Motility 
One possible mechanism leading to the alterations in MS-related GI motility involves the 
role of serotonin. Serotonin (5-hydroxytryptamine; 5-HT) is an intercellular signaling molecule 
that initiates, regulates, and modifies GI motility, secretion, and vasodilation (Spohn & Mawe, 
2017). The majority of 5-HT in the body is synthesized in the GI tract, with a subtype of 
enteroendocrine cell, the enterochromaffin cell, being the primary source of 5-HT. 
Enterochromaffin cells function as sensory transducers and use the rate limiting molecule 
tryptophan hydroxylase 1 (Tph1) to initiate the synthesis of L-tryptophan to 5-HT. Unlike 
acetylcholine, 5-HT does not have a counterpart intercellular degrative enzyme to terminate 
signaling, and thus requires a specialized transport molecule, serotonin selective reuptake 
transporter (SERT), to remove 5-HT from the intercellular space and stop receptor activation. Once 
it is transported, 5-HT can be recycled into vesicles or degraded by monoamine oxidase (Mawe & 
Hoffman, 2013).  
Serotonin signaling has been investigated in animal models of GI inflammatory diseases 
and in human samples from ulcerative colitis and diverticulitis patients. An alteration consistent 
in these conditions is decreased epithelial expression of SERT with the exact 5-HT signaling 
pathway alterations varying for each disease (Coates et al., 2017). As MS is associated with 
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inflammation, it stands to reason that a contributing factor of this inflammation and GI dysfunction 
could correspond to altered levels of 5-HT and SERT. This is supported by preliminary data from 
the Mawe lab examining 5-HT levels outside the epithelium in colon preparations of EAE versus 
control mice using amperometry. In these experiments, 5-HT was measured at the mucosal surface. 
These findings showed that there was a significantly higher concentration of 5-HT measured at the 
mucosal surface of colons from the EAE mice (figure 1 A), and that this difference was eliminated 
in the presence of fluoxetine, a SERT inhibitor (figure 1 B). These data suggest an alteration of 5-
HT signaling in EAE in correlation to a decreased expression and/or function of SERT. Based on 
this preliminary data and previous literature it could be suggested that an alteration in 5-HT 
mechanisms might be associated with the GI dysfunction exhibited by the EAE model. This led to 
the hypothesis that there is an increase in 5-HT availability in the EAE GI tract driven by a 






Sex Differences in Multiple Sclerosis/EAE 
 As previously mentioned, it has been validated that the EAE model demonstrates GI 
dysmotility consistent with that of MS (Spear et al., 2018; Wunsch et al., 2017). However, the 
strains of mice selected and sex of the animals used for studies have varied across experiments, 
yielding slightly different results in susceptibility to EAE depending on these variables 
(Constantinescu et al., 2011). This is somewhat consistent with the general heterogeneric nature 
of MS as a whole and its sexually dimorphic characteristics. In fact, the EAE model has been 
utilized to examine sex differences in disease presentation of MS (Spach et al., 2009; Teuscher et 
al., 2004, 2006). These studies have shown that there is both an involvement of the Y chromosome 
as well as an age dependent factor in disease susceptibility in the model (Spach et al., 2009; 
Teuscher et al., 2006). Similarly, investigations along these lines have indicated that the sex of the 
mouse is the strongest contributing factor in the development of the hallmark brain and spinal cord 
lesions associated with EAE when also taking into consideration the age of the mouse and season 
of induction of the disease (Teuscher et al., 2004). Despite this critical investigation into possible 
sex differences within the EAE model, most of the work to date has focused on differences within 
the CNS derived symptomology of EAE and does not indicate whether or not these differences in 
susceptibility and effectiveness as a model might exist in the ENS, specifically in terms of 
modeling GI dysmotility. 
That said, previous data from the Mawe lab has predominately focused on the use of male 
mice. This focus was derived from the fact that male mice in the hands of the Mawe lab have 
demonstrated a high rate of consistent EAE disease presentation in terms of characteristic motor 
symptoms ranging from tail weakness to quadriplegic status and have therefore been most 
associated with GI dysfunction, whereas female mice tend to classify as asymptomatic. Despite 
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this, preliminary data from the Mawe lab has shown that female mice reported to be largely 
asymptomatic, or did not develop severe motor symptoms, still showed altered fecal water content 
(figure 2 A), which would be consistent with GI dysfunction. These data appear to indicate that GI 
symptoms can be associated with mice that present as asymptomatic, as do most female mice in 
the Mawe lab studies, supporting the idea that female and male mice could represent comparable 
MS GI dysmotility models despite the apparent difference in EAE susceptibility between the two 
sexes. 
Further supporting this possibility, a population of asymptomatic male mice in a recent 
study by the Mawe lab showed that there was an increase in colonic transit time (slower motility) 
measured using the bead expulsion assay (figure 2 B) and therefore could be classified as having 
altered GI motility despite presenting without the classical EAE motor symptoms. Collectively, 
however, these data were not strong enough to conclude that asymptomatic mice will exhibit GI 
dysfunction, as there is still a strong correlation between an increase in motor symptom severity 
and GI dysfunction. This leaves much to speculation as to whether or not mice that are 
asymptomatic, such as the female population used in the Mawe lab, actually develop GI 
dysfunction comparable to the symptomatic male mice. Therefore, based on these preliminary 
data, we tested the hypothesis that female mice can in fact serve as comparable models to their 









As can be seen from gaps in the literature, there is still much to be discovered in terms of 
the implications between the ENS and MS and the impact on GI dysfunction. In this regard, it is 
the goal of this study to contribute to the field by providing a novel assessment on the role of 
mucosal 5-HT signaling within the EAE GI tract and the potential sex differences in GI motility 
of EAE mice. This assessment was accomplished through both molecular and in vivo motility 
assays. The molecular assays, including RT-qPCR to examine Tph1 and SERT mRNA expression 
and an enzyme-linked immunosorbent assay (ELISA) to assess the tissue 5-HT content, were 
utilized to fulfil the goal of examining key elements of 5-HT signaling. In parallel, the in vivo GI 
motility assays, including an analysis of colonic motility as assessed by bead expulsion, 
constipation as measured by fecal water content, and an examination of whole GI transit, allowed 





 For the in vivo GI motility assays used in this study, two cohorts of female and male 
C57BL/6J mice approximately 8 weeks of age were utilized. The first cohort of mice were obtained 
from within the Sox10/GCAMP transgenic C57BL/6J mouse line of the Mawe lab mouse colony 
and consisted of 26 mice (14 EAE and 12 controls, which comprised of 7 EAE female/males and 
6 control female/males). Similarly, the second cohort of mice were C57BL/6J mice purchased 
from Jackson Labs, Bar Harbor, ME, and had a total of 38 mice (19 EAE and 19 controls, which 
comprised of 9 female controls, 10 male controls, 10 female EAE, and 9 male EAE). All 
experimental animal protocols used for this study were approved by University of Vermont 
Institutional Animal Care and Use Committee. 
 
EAE Induction 
Female and male C57BL/6J mice were randomly divided into control and experimental 
condition groups. The experimental conditioned mice were induced with EAE using the 2X MOG 
protocol, as follows. Mice were immunized with a sonicated emulsion of myelin oligodendrocyte 
glycoprotein peptide (MOG35-55) and complete Freund’s adjuvant (CFA) containing 200 μg 
Mycobacterium tuberculosis H37RA (Becton Dickinson & Co). The mice then underwent a 2X 
induction protocol, in which they received two posterior right and left flank subcutaneous 
injections of the emulsion each a week apart with the second injection being anterior to the initial 
injection site as previously described (Spear et al., 2018). The control mice followed the same 
protocol, however they only received CFA injections. Daily evaluations included recordings of 
weight and disease severity scores beginning 14 days postimmunization until the end of the trial 
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on day 28 as previously described (Spear et al., 2018). EAE disease scoring was based off of a 0 
to 5 scale in which a 0 was asymptomatic, 1 was tail paralysis, 2 was tail paralysis and hind limb 
weakness, 3 was tail and hind limb paralysis, 4 was tail and hind limb paralysis and urinary 
incontinence, and 5 was moribund. Once a mouse reached a score of 3, food pellets and Napa 
Nectar were placed at the bottom of the cage to assure nutrient uptake. Fluid injections were also 
given to mice if they were noted to have lost 30 percent of their initial body weight, mice that 
consistently lost weight at this percentage and did not respond to fluid injections were euthanized. 
Cumulative disease scores were calculated by adding together the daily somatic disease scores 
across the span of the experiment to represent the total disease score accrued.  
 
GI Motility Assays 
 Three assays were utilized to assess in vivo GI motility: bead expulsion, fecal output and 
water content, and an evaluation of whole GI transit. Bead expulsion and fecal water content were 
conducted both as a baseline measure on day 0 before induction of EAE as well as an experimental 
measure, whereas the whole GI transit was only conducted as an experimental measure. All 
motility assays were completed by day 28 of the experiment, with the fecal water and bead 
expulsion assays occurring on day 27 and the whole GI transit assay occurring on day 28. The 
second cohort of mice also underwent an additional GI motility time point assessment at day 21.  
 
Bead Expulsion 
 The bead expulsion assay was utilized to assess colonic transit time. Mice were lightly 
anesthetized with isoflurane and a 2.3 mm bead was inserted approximately 20 mm into the distal 
colon using a blunt gavage needle. Time of bead insertion, time of recovery from anesthesia, and 
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time of bead expulsion were all recorded, allowing for an assessment of total colonic transit time 
as measured by the time elapsed between insertion and bead expulsion. This assay was conducted 
as a baseline measure before the induction of EAE and as an experimental measure at day 27 to 
allow for a comparison in terms of progression of symptoms. The second cohort of mice also 
underwent another time point assessment, in addition to the one at day 27, at day 21 to allow for a 
more in-depth analysis of colonic motility during the disease course.  
 
Fecal Water Content 
 Each mouse was placed in an individual cage and monitored for 1 hour. During this time, 
deposited fecal pellets were collected and weighed. The pellets were then dried for a period of 24 
hours at 50◦C and reweighed to allow for a calculation of fecal water content. The number of pellets 
was also recorded in order to better understand the changes in motility. This assay was conducted 
as a baseline measure before the induction of EAE and as an experimental measure at day 27. The 
second cohort of mice also underwent another time point assessment, in addition to the one at day 
27, at day 21 to allow for a more in-depth analysis of potential GI dysmotility during the EAE 
disease course.  
 
Whole GI Transit 
 Mice were placed in individual cages without bedding and administered an oral gavage of 
300 μl 6% carmine red and 0.5% methylcellulose (Sigma Aldrich) in water. They were then given 
food and water ad libitum and monitored until carmine red was noted in the fecal pellets, indicating 





 After completion of the 28-day experimental period following previous Mawe lab 
procedures, the mice were euthanatized and their colons dissected and separated into six segments 
for potential use in molecular analysis.  
 
Examination of 5-HT Signaling 
 For the purpose of this portion of the study previously obtained EAE and control colon 
segments from C57BL/6J were utilized. These colon segments were stored at -80◦C and originated 
from experiments related to the Spear et al. study, following the 2X MOG protocol. Key aspects 
of 5-HT signaling were assessed including mRNA expression of the synthetic enzyme, tryptophan 
hydroxylase 1 (Tph1), and serotonin selective reuptake transporter (SERT) using RT-qPCR, as 
well as tissue 5-HT content using an enzyme-linked immunosorbent assay (ELISA).  
 
RT-qPCR 
For the purpose of this study RT-qPCR was utilized in order to examine the mRNA 
expression of 5-HT, as measured by Tph1 and SERT (primers obtained from Thermofisher). RNA 
was extracted from colon preparations using a RNeasy Mini Kit (Qiagen) and analyzed using a 
NanoDrop Spectrophotometer in the COBRE laboratory. Samples then underwent RT-PCR to 
convert the isolated RNA to stable cDNA for use in qPCR experiments. All qPCR experiments 
were conducted using Applied Biosystems 7500 Fast Real-Time PCR System under Standard 7500 
Mode in the COBRE laboratory, therefore yielding a quantification of mRNA expression of Tph1 
and SERT in EAE samples relative to control samples. These data were then normalized to a 
selected housekeeper gene, beta 2 microglobulin (B2M), that demonstrated no significant 
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difference between the groups despite experimental condition, allowing for a more accurate 
analysis of mRNA expression between groups. 
 
ELISA 
A 5-HT ELISA kit (Beckman Coulter) was used to directly examine the tissue 5-HT 
content in the GI tract of EAE versus control mice as quantified by the microplate reader in the 
COBRE laboratory and standardized using a known concentration serotonin solution ranging from 
0 nM – 200 nM. These data were then normalized to the total amount of protein present in the 
samples through use of bicinchoninic acid assay with the Pierce BCA kit (Thermofisher). 
 
Statistical Analysis  
 All statistical analysis was completed using GraphPad Prism for Windows 7. Data were 
analyzed using an unpaired t test in order to determine statistical significance. Additionally, 
outliers were identified and excluded from the data sets using a Q test (2 standard deviations from 






Female and male mice have similar disease score characteristics 
 Cumulative disease score was obtained through an addition of the daily somatic disease 
scores across the total experimental period, allowing for an illustration of the total disease severity. 
There was no significant difference between the female EAE and male EAE cumulative disease 
scores in either the first or second cohort of mice (figure 3). These data suggests that both female 
and male EAE mice establish a similar degree of disease severity across the experimental period.  
 The day of disease onset was determined based on the first experimental day that a score 
other than 0, asymptomatic, was recorded. There was no significant difference between female and 
male EAE mice in the day of disease onset for either the first or second cohort (figure 4). These 
data suggest that female and male EAE mice have a similar systemic disease onset time course as 
measured by the EAE scoring protocol.  
 Average daily disease scores across the experimental period were examined in order to 
investigate the potential differences in disease activity for female and male mice. Visually the 
disease activity was closely mirrored between female and male mice in both cohorts (figure 5 A 
& B), with the caveat that female mice in the second cohort presented with disease activity that 
was generally slightly less severe than male mice (figure 5 B). Additionally, male mice were shown 
to have a slightly higher average daily disease score than female mice around experimental day 21 
in both cohorts (figure 5 A & B). In contrast, female mice were shown to have a slightly higher 
average daily disease score than males on experimental day 17 and 18 for the first and second 
cohort respectively (figure 5 A & B). However, analysis of these individual time points shows no 
significant difference between female and male daily disease activity (figure 5 C - F). Taken 










Female and male mice represent comparable GI motility models 
Bead expulsion, fecal water content, and whole GI transit were all utilized to assess the 
possibility of sex derived motility differences in the EAE mouse model. Bead expulsion allowed 
for an assessment of colonic motility, measured through the time elapsed between bead insertion 
and expulsion. As previously demonstrated by experiments in the Mawe lab, bead expulsion on 
experimental day 27 for the combined EAE female and male mice was shown to be significantly 
slower than control mice for both cohort one, P = 0.0268, and cohort two, P = 0. 0037 (figure 6), 
signifying delayed colonic motility in EAE mice. However, no significant difference was noted 
amongst both studied cohorts of mice when comparing female EAE to male EAE mice (figure 7). 
17 
 
These data suggest that both female and male mice exhibit comparable levels of GI dysfunction in 






Fecal water content was also used as a measure of GI dysfunction through an assessment 
of constipation, in that a smaller percentage of water indicates drier fecal pellets consistent with 
constipation. For this particular assay, the first and second cohort results for the combined female 
and male EAE mice as opposed to the controls presented differently. Consistent with the previous 
experiments from the Mawe lab, the EAE mice in the first cohort demonstrated a significant 
decrease in water content as compared to controls, P = 0.0444 (figure 8 A), whereas, the second 
cohort showed no significant difference between the control and EAE mice (figure 8 B). These 
data suggest that the first cohort of EAE mice showed GI dysfunction consistent with constipation 
while the second cohort of EAE mice did not present with decreased fecal water content. When 
examined by sex, it was found that there was no significant difference between the female EAE 
and male EAE mice across both cohorts (figure 9). These data then suggest that both female and 





 Finally, whole GI transit, as measured by the time after oral gavage of carmine red dye to 
the presence of the dye within the fecal pellets, was noted to not be significantly different in either 
cohort when examining the total female and male EAE mice as compared to control mice (figure 
10 A & C). These data would suggest that for these two cohorts of mice, at the time point that was 
studied, GI dysfunction did not reach an extent of decreased whole GI transit as has been 
previously seen in experiments by the Mawe lab. Additionally, there was no significant difference 
noted between the first cohort of female EAE versus male EAE mice in terms of whole GI transit 
time (figure 10 B). In contrast, the second cohort of female EAE versus male EAE mice that 
showed a slower whole GI transit in female EAE mice as opposed to males (figure 10 D). In this 
regard, the data from the first cohort of mice suggests that both female and male EAE mice present 
with a comparable degree of GI dysfunction. However, the data from the second cohort of mice 
suggests that female EAE mice have a slower GI transit time than males, presenting a possible sex 
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Female and male mice have different peak colonic dysmotility time points 
 As mentioned previously, colonic motility was assessed using bead expulsion. For the 
second cohort of mice two separate time points, 21 and 27 days into the experimental protocol, 
were utilized in order to assess the level of colonic dysmotility, spurred by separate concurrent 
experimentation in the Mawe lab which will be discussed in greater detail bellow. Bead expulsion 
at day 21 showed a significant increase, P = 0.0411, in expulsion time for male EAE mice as 
opposed to male control mice (figure 11 B), indicating slowed colonic motility and GI dysfunction. 
This is in contrast to the female EAE and control mice which did not significantly differ from each 
other on day 21 (figure 11 A). Bead expulsion at day 27 showed a significant increase, P = 0.006, 
in expulsion time for female EAE mice as opposed to female control mice (figure 11 C), indicating 
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slowed colonic motility and GI dysfunction. These data at day 27 are in contrast with the male 
EAE and control mice which did not significantly differ from each other at the selected time point 
(figure 11 D). Taken together the bead expulsion data from day 21 and day 27 suggest that female 
and male EAE mice differ in the peak onset of GI dysfunction, with male EAE mice most 
prominently presenting with slowed colonic motility at day 21 and female EAE mice 





Altered GI motility is not directly tied to changes in 5-HT signaling 
 To assess the role of 5-HT in GI dysfunction of EAE mice, molecular assays were utilized 
to examine mucosal 5-HT signaling in various stages including mRNA expression for critical 5-
HT signaling molecules and for and tissue 5-HT content. RT-qPCR was utilized to assess the 
mRNA expression of serotonin selective reuptake transporter (SERT) and the synthetic enzyme, 
tryptophan hydroxylase 1 (Tph1) to elucidate an understanding of 5-HT mRNA expression. 
mRNA expression was normalized to the housekeeper gene beta 2 microglobulin (B2M), as this 
gene showed no significant difference between both the experimental and control conditions. Final 
analysis showed that there was a significant, albeit modest, decrease in Tph1 expression between 
EAE and control mice, P = 0.046 (figure 12 A); however, there was no significant difference in 
SERT expression between EAE and control mice (figure 12 B). These data indicate that there is a 
potential alteration in 5-HT synthesis, due to the decrease in Tph1 expression, however this is not 
mirrored in the expression of SERT, suggesting that any possible changes to the 5-HT pathway 
would not be mediated by SERT.  
Tissue 5-HT content was assessed using an enzyme-linked immunosorbent assay (ELISA) 
and the obtained data was normalized against the total quantity of proteins present in the tissue, as 
determined by a bicinchoninic acid assay. These data showed that there was no significant 
difference in tissue 5-HT content in EAE mice as compared to controls (figure 13). Taken together 
with the data from the RT-qPCR assay, these data suggest that the dysmotility noted in the EAE 











 This study aimed to gain a deeper understanding of the involvement of the ENS in GI 
dysfunction in the EAE mouse model of MS, specifically examining the role of mucosal 5-HT 
signaling and the potential sex derived motor activity differences within the model. The findings 
presented suggest that the alterations in GI motility seen in the EAE model are not driven by 
changes to mucosal 5-HT signaling. Additionally, the results demonstrated that both female and 
male EAE mice induced under the 2X MOG protocol present with similar extents of GI 
dysfunction though the time course of said dysfunction differs by 6 days between the sexes.  
  
Female and male mice can both serve as models of MS-related GI dysfunction 
 As mentioned previously, many studies utilizing the EAE mouse model of MS have 
differed in the use of the selected strain, sex, and method of EAE induction. The Mawe lab is no 
exception to this claim, as most of the EAE studies completed have predominately utilized male 
mice, as they were previously shown to be most consistent in demonstrating EAE symptomology 
and are therefore thought to be the ideal model for assessments of GI dysfunction. However, this 
study suggests that female and male EAE C57BL/6J mice induced utilizing the 2X MOG protocol 
are comparable models in terms of the extent of presented GI dysfunction based upon the in vivo 
assays as well as the disease activity characteristics and can therefore be used in conjunction with 
one another. These findings then alter the paradigm for the selected use of one sex over the other 






Multiple time point analysis 
 While the results of this study suggest that female and male mice represent comparable 
models , these findings also suggest that there are transient differences between the two sexes. 
Most notably the discovery that female and male mice have differing peak time points for colonic 
dysmotility as analyzed by bead expulsion. As previously mentioned, these findings were spurred 
by separate concurrent research in the Mawe lab. This separate experimentation was designed with 
the purpose of discovering the optimal experimental time course to examine consistent GI 
dysfunction under the 2X MOG induction method of EAE in male mice. Data from that 
experimentation revealed that colonic dysmotility could be noted at day 21, which was earlier than 
the previously utilized time point in the Mawe lab (data not shown). Following this trend of data, 
the new checkpoint was added to the second cohort of mice with the expectation that there would 
be notable colonic dysmotility in males on day 21. As this concurrent investigation utilized only 
male mice however, the motility outcome for female mice was unknown. The finding that female 
and male mice differ in peak colonic dysmotility added a new aspect to the analysis of potential 
sex derived differences in the motor activity of EAE mice. This once again shifts the paradigm and 
understanding of the utilization of the EAE mouse model for examination of GI dysmotility. While 
it can be said that these models are comparable to one another based on the fact that no significant 
difference was noted between the selected in vivo assays and can therefore be used in conjunction 
with one another, it cannot be discounted that there are still possible mechanistic differences 






Differences in in vivo motility assays 
Whole GI transit 
 Previous studies by the Mawe lab, specifically reported in Spear et al., demonstrated that 
EAE mice present with delayed whole GI transit, however these findings were not mirrored in this 
study at the selected time point analysis. This difference between these two studies is most likely 
derived from mechanisms concerning gastric emptying. As shown in Spear et al. it has been 
suggested that EAE mice present with accelerated gastric emptying and no changes in small 
intestinal motility in relation to control mice (Spear et al., 2018). In turn, based on these findings 
it is possible that an increase in gastric emptying without a change in small intestinal motility could 
compensate for a reduction in colonic motility, resulting in a whole GI transit that is not 
significantly different from the controls, as was seen in this study.  
 Similarly, the fact that female EAE mice had a significantly slower whole GI transit than 
male EAE mice in the second cohort again implicates the suggested time component difference of 
GI motor activity between female and male EAE mice. As was suggested by the findings of the 
bead expulsion assay, female mice experience peak colonic dysmotility at day 27 as opposed to 
males which experience peak colonic dysmotility at day 21. Since the whole GI transit assay is 
conducted at day 28, only one day after the stated peak colonic dysmotility time point for females, 
it stands to reason that female mice would have a slower GI transit time compared to males. This 
could be explained through the mechanism that the noted increased gastric emptying in EAE mice 
might not be able to compensate as strongly for the greater extent of delayed colonic motility seen 
in females as compared to males. While this difference does exist between female and male mice 
in the second cohort for whole GI transit, the general results of the assay are unchanged. Female 
mice when compared to their respective controls show no significant difference in whole GI transit, 
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nor do males against their respective controls, leading to the general reported nonsignificant results 
of the assay. Additionally, these findings in conjunction with the difference in peak colonic 
motility time points suggest that there might be alterations in the molecular underpinnings of the 
2X MOG EAE model between female and male mice, however these differences do not impact 
the general results of the in vivo motility assays allowing for both sexes to serve as comparable 
models. 
 
Fecal water content 
 Previous results concerning fecal water content of EAE mice have generally shown a 
smaller percentage of water content in EAE mice than controls. These findings suggest that EAE 
mice tend to have alterations in secretion and absorption in conjunction to the noted dysmotility 
features (Spear et al., 2018). However, the results from the current study in terms of fecal water 
content are much more dichotomized between the two cohorts for the total EAE and control groups 
of mice. In this sense, the first cohort of mice is consistent with the previously conducted studies 
by the Mawe lab, however the second cohort presents a different story. The results from the second 
cohort suggest that there is not a difference in the levels of absorption or secretion within the GI 
tract between EAE and control mice. However, these findings also need to be examined in 
conjunction to the assessment of colonic motility through bead expulsion. These data show that 
for the selected time point, day 27, there is a significant difference between the total EAE and 
control groups, indicating that there is colonic dysmotility present within the EAE group. 
Therefore, the findings of the fecal water content assay indicate that for that the second cohort of 




Variability of data from EAE models 
While the variability of EAE presentation between the sexes and strains of mice has been 
commonly recognized in the literature, there has also been noted to be a level of variability in EAE 
presentation and GI dysfunction from experiment to experiment as well as between studies 
utilizing the same induction method. This particular phenomenon was noted in this current study, 
as was just mentioned in the fecal water content assays, as well as when comparing this study to 
previous investigations in the Mawe lab utilizing the 2X MOG induction protocol. These 
variability differences are most likely derived from the complexity of EAE pathogenesis. It is 
currently thought that the EAE mechanism for the MOG protocol involves the activation of the 
immune system, through the foreign presentation of MOG. This immune response, specifically the 
activated T cells primed against MOG, then enter the CNS and cause the destruction of myelin, 
due to the presence of the MOG peptide. In turn, the effects of the immune response cause the 
production of antibodies by B cells which can interact with enteric neurons and glial mediating the 
GI dysfunction observed in the model, as was supported by Spear et al., that showed that B cell 
deficient EAE mice did not demonstrate altered GI motility (Spear et al., 2018). It is from this 
multitude of processes involved in EAE pathogenesis that many levels of variability can exist, 
purely based on immune system signaling, regulation, and response to the MOG induction, 
creating the possibility of differing extents of disease severity and GI dysfunction while utilizing 
the same experimental protocol. 
 Similarly, for female mice in particular, the stage of the estrous cycle can impact the 
presentation of EAE severity and symptomology. A recent study suggested that female mice in 
proestrus, the stage of the estrus cycle characterized by an elevated expression of estrogen and 
progesterone, demonstrated attenuated EAE symptomology as induced using MOG, both in terms 
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of disease score and neurological motor impairment. Likewise, the same study reported that the 
administration of CFA or an emulsion of CFA and MOG had a tendency to prolong the amount of 
time spent in diestrus, therefore altering the timing of the normal estrous cycle (Rahn, Iannitti, 
Donahue, & Taylor, 2014). Viewed together, these findings implicate the role of the estrous cycle 
on EAE variability, as desynchrony in the estrous cycle between females could alter individual 
EAE disease presentation and impact the obtained experimental data. 
On a more environmental level however, the involvement of the gut microbiome has also 
been implicated in EAE susceptibility and severity (Chu et al., 2018). That said, it is well known 
that the gut microbiome also has a predominant influence on GI activity. Taken together, these 
factors suggest that separate cohorts of mice could respond differently to an induction of EAE 
depending on the expression of bacteria within their GI tract, even if they are from the same strain 
of mice, demonstrating another potential avenue for variability of data from EAE models.  
 
5-HT signaling and the search for a stable housekeeper gene 
 While alterations in 5-HT signaling have been implicated in various GI inflammatory 
diseases, including ulcerative colitis and diverticulitis (Coates et al., 2017), the current study 
suggests that changes in mucosal 5-HT signaling are not a causal agent behind the reported GI 
dysfunction in the EAE mouse model of MS. This assessment was primarily obtained through the 
use of RT-qPCR as this allowed for an mRNA derived analysis of SERT, which was the 
hypothesized driving force behind the possible alterations in 5-HT signaling and has been 
confirmed to be altered in the previously mentioned GI inflammatory diseases.  
 The caveat to the use of RT-qPCR in this study however, was the ability to find a stable 
housekeeper gene which could be used to normalize the results between both the EAE and control 
30 
 
conditions. Previous experimentation in the Mawe lab has commonly relied on the use of 
hypoxanthine phosphoribosyltransferase (HPRT) and ubiquitin (UBC) as the housekeeper genes, 
since both of these genes have been shown to be stable between the different conditions. However, 
when these genes were tested for this particular study there was a significant decrease in the mRNA 
expression for both HPRT and UBC in EAE mice, negating their use for normalizing RT-qPCR 
data in the current study. An in-depth literature search was conducted in order to determine other 
possible suitable housekeeper genes. As very little work has been completed utilizing RT-qPCR 
to examine mRNA expression in EAE colon tissue, the chosen reviews by Eissa et al. focused on 
RT-qPCR in inflamed colonic tissue from the mouse model of colitis, as this model would 
hypothetically be similar to the GI inflammation and dysmotility in EAE mice (Eissa et al., 2016; 
Eissa, Kermarrec, Hussein, Bernstein, & Ghia, 2017). From these reviews, as well as previous 
Mawe lab experimentation, six other possible housekeeper genes were selected as potential 
candidates. These genes included 18s ribosomal RNA, eukaryotic translation elongation factor 2 
(Eef2), phosphomannomutase 1 (PMM1), TATA-box binding protein (Tbp), glucuronidase beta 
(Gusb), and beta 2 microglobulin (B2M). Of these tested genes, only B2M was shown to have no 
significant difference between the EAE and control group. All other tested genes demonstrated a 
significant decrease in mRNA expression of the selected gene in EAE samples as compared to 
controls (data not shown). This appears to indicate that there might be a mechanism of molecular 
degradation that is higher or altered in EAE mice as compared to controls, leading to this trend. 
Therefore, a more thorough analysis of RT-qPCR techniques utilizing EAE colon tissue is needed 
in order to better understand future applications of RT-qPCR in EAE derived samples and to 




Choice of statistical analysis 
The statistical analysis and conclusions for this study were possible due to the ability to 
examine the data in a sub-grouped manner, examining both the total EAE and control populations 
as well as the specific subsets of female and male EAE and control mice. It can be recognized that 
at a glance there could be issues with the selected sub-grouped methodology instead of looking at 
all four data sets (female EAE, female control, male EAE and male control) as a whole entity using 
a two-way ANOVA following statistical conventions. However, this study was designed with 
purpose of determining the possible differences between two specific groups, female and male 
EAE mice, therefore justifying the separation of data analysis. 
 
Future directions 
Deeper examination of 5-HT signaling 
 As mentioned previously, this study’s design relied on an examination of mRNA 
expression to ascertain possible alterations in SERT. However, this analysis method only allowed 
for an indirect evaluation of the SERT mechanism and its involvement in 5-HT signaling. In this 
sense, it is possible that there are alterations in the protein level, post translational modifications, 
or protein function of SERT which could corroborate with the amperometry preliminary data seen 
in the Mawe lab, in which addition of a SERT inhibitor normalized 5-HT release between EAE 
and control tissue. Therefore, a functional study of SERT changes is necessary in order to better 
understand the true implications behind the involvement of SERT in mucosal 5-HT signaling in 
the EAE model. 
 Likewise, the results from this study concerning the decreased mRNA expression of Tph1 
also provides an area of future study. 5-HT is synthesized in enterochromaffin cells which use the 
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rate limiting enzyme Tph1 to convert L-tryptophan to 5-HT (Mawe & Hoffman, 2013). In this 
sense, an analysis of enterochromaffin cells would provide insight into a possible explanation as 
to why this study found that there was a decrease in Tph1 mRNA expression without any noted 
alterations to tissue 5-HT content. One possible avenue for exploration would include the use of 
immunohistochemistry to stain enterochromaffin cells utilizing a goat anti-5-HT polyclonal 
antibody labeled with donkey anti-goat Cy3 as previously described (Hoffman et al., 2012). These 
stained cells could then be manually counted based on numbers of cells per colonic gland as 
previously described (Linden et al., 2005), allowing for an assessment in the  prevalence of 
enterochromaffin cells for 5-HT synthesis. The potential of including this work as a future aim in 
studies has already been discussed in the Mawe lab. 
 
Sex derived difference experimentation 
The difference in findings between cohorts for in vivo GI motility assays demonstrated in 
this study alludes to the concept that there are transient effects in examining GI dysfunction within 
the EAE model using the 2X MOG protocol. Both of these two cohorts were induced under the 
same protocol and followed the same time course assessment, with the exception of an additional 
time point for bead expulsion and fecal water content at day 21 utilized for the second cohort. 
However, despite this similarity in protocol there are differences between the two cohorts in terms 
of reported significance of the results, the possible reasoning behind this being previously 
addressed. Similarly, the fact that this current study failed to replicate the results for whole GI 
transit as was seen in Spear et al. utilizing the same strain of mice, induction method, and time 
course again illustrates the transient nature of GI symptoms in the 2X MOG EAE model. Taken 
together, it is therefore suggested that future studies explore the possible sex differences in motor 
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activity in a more consistently robust induction method of the EAE model in terms of GI 
dysfunction in order to truly ascertain the impact of sex on GI motor activity across multiple 
variations of the EAE model. 
 In addition to the use of different EAE models for investigation into the greater translatable 
potential effects of sex on motor activity, this study also spurred many questions about the possible 
effects of estrogen on EAE in the GI tract. Previous studies have suggested that elevated levels of 
estrogen can reduce EAE symptomology (Haghmorad et al., 2016; Polanczyk et al., 2003) and that 
the position within the estrous cycle can have an impact on EAE presentation and neurological 
motor impairment (Rahn et al., 2014). However, very little research has specifically examined the 
implications of estrogen on GI motility and symptomology in the GI tract of EAE mice. Therefore, 
future aims of this research might attempt to quantify estrogen levels during the EAE experimental 
period to potentially correlate estrogen expression with the GI symptomology time line. Similarly, 
it might be beneficial to study mice with synchronized estrous cycles in order to potentially negate 
estrous cycle derived variability in the EAE model. This line of inquiry would therefore allow for 
a better understanding of the possible differences in peak GI dysmotility time points noted between 
female and male mice. 
 Along these lines it is also suggested that a more thorough molecular examination into the 
potential sex derived GI dysmotility peak onset times be investigated. Previous work in the Mawe 
lab has indicated that the GI dysfunction seen in EAE mice is B cell mediated and involves the 
targeting of autoantibodies (Spear et al., 2018). In this sense, future research might aim to examine 
if there are any differences in the circulation of cytokine factors, which are involved in 
inflammation, or B cell maturation between female and male mice that might account for the 
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